What is the 13F Pro Quality Score for INBS?

13F Pro ranks INTELLIGENT BIO SOLUTIONS INC. (INBS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INBS's current score at https://13fpro.ai/company/INBS (free sign-up required for the full ranking).

Where does 13F Pro source INBS data?

All INTELLIGENT BIO SOLUTIONS INC. fundamentals and ownership data come directly from SEC EDGAR. INTELLIGENT BIO SOLUTIONS INC. files with the SEC under CIK 1725430. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INBS in?

INTELLIGENT BIO SOLUTIONS INC. (INBS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INBS research updated on 13F Pro?

INBS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

INTELLIGENT BIO SOLUTIONS INC.(INBS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1725430 INBS stock profile & AI dashboard →

13F Pro Quality Score

23.2/100

Rank #2,677 of 2,884 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

81.6/100

Profitability

4.6/100

Balance Sheet

1.0/100

Earnings Quality

11.2/100

Free Cash Flow

4.0/100

Institutional Flow

13.0/100

Revenue Scale

1.8/100

Dilution Risk

38.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why INBS Scores 23/100

exact factor attribution · 2026-08-18

INBS's composite is driven by revenue growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.3 pts

82th pct

Shareholder dilution

-0.6 pts

38th pct

Earnings growth

-1.0 pts

30th pct

Institutional flow

-1.9 pts

13th pct

Earnings quality

-3.9 pts

11th pct

Capital efficiency

-4.9 pts

1th pct

Profitability

-6.8 pts

5th pct

Free cash flow

-6.9 pts

4th pct

Scale

-7.2 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

INBS Stock Analysis & AI Quality Score

Data updated 2026-08-18

AI stock analysis and institutional research for INTELLIGENT BIO SOLUTIONS INC. (INBS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INBS at 23.2/100 on a 32-signal composite quality model, placing it at rank #2,677 of 2,884 stocks — the bottom half of the AI-ranked universe. INBS scores in the top quartile across revenue growth (81.6). Areas of concern include balance sheet strength (1.0) and revenue scale (1.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), INTELLIGENT BIO SOLUTIONS INC. reports quarterly revenue of $1.1M, net income of $-3.9M, free cash flow of $-3.2M. Top institutional holders of INBS by reported 13-F value include ARMISTICE CAPITAL, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. INBS trades on the Nasdaq exchange and files with the SEC under CIK 1725430. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INBS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INTELLIGENT BIO SOLUTIONS INC. directly from SEC EDGAR.

Revenue

Q2 2026

$1.1M

Net Income

Q2 2026

$-3.9M

Free Cash Flow

Q2 2026

$-3.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+38.1% YoY

$4.2MFY 2026

FY23 $1.3MFY24 $3.1MFY25 $3.1MFY26 $4.2M

Net Income

-17.6% YoY

$-12.4MFY 2026

FY23 $-10.6MFY24 $-10.2MFY25 $-10.6MFY26 $-12.4M

Operating Income

-18.1% YoY

$-12.6MFY 2026

FY23 $-12.6MFY24 $-10.3MFY25 $-10.7MFY26 $-12.6M

EPS (Diluted)

+57.9% YoY

$-8.44FY 2026

FY23 $-105.83FY24 $-6.38FY25 $-20.04FY26 $-8.44

Total Assets

+44.8% YoY

$11.9MFY 2026

FY23 $10.4MFY24 $13.8MFY25 $8.2MFY26 $11.9M

Total Debt

—FY 2026

FY23 —FY24 $1.6MFY25 —FY26 —

Op. Cash Flow

-23.2% YoY

$-11.9MFY 2026

FY23 $-7.4MFY24 $-9.6MFY25 $-9.7MFY26 $-11.9M

Free Cash Flow

-21.6% YoY

$-12.1MFY 2026

FY23 —FY24 $-9.8MFY25 $-9.9MFY26 $-12.1M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$4.2M +38.1%	$3.1M -1.9%	$3.1M +147.6%	$1.3M +187.5%	$437.1K -77.9%	$2.0M
Net Income	$-12.4M -17.6%	$-10.6M -4.1%	$-10.2M +4.5%	$-10.6M -28.0%	$-8.3M -18.0%	$-7.0M
Operating Income	$-12.6M -18.1%	$-10.7M -3.9%	$-10.3M +18.4%	$-12.6M -51.1%	$-8.3M -49.6%	$-5.6M
EPS (Diluted)	$-8.44 +57.9%	$-20.04 -214.1%	$-6.38 +94.0%	$-105.83 -1020.9%	$-9.44	—
Total Assets	$11.9M +44.8%	$8.2M -40.1%	$13.8M +33.1%	$10.4M -16.2%	$12.4M -43.5%	$21.9M
Total Debt	—	—	$1.6M	—	—	—
Operating Cash Flow	$-11.9M -23.2%	$-9.7M -1.1%	$-9.6M -29.7%	$-7.4M -119.7%	$-3.4M +70.3%	$-11.3M
Free Cash Flow	$-12.1M -21.6%	$-9.9M -1.2%	$-9.8M	—	—	—

Get alerted when INBS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for INTELLIGENT BIO SOLUTIONS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INBS

ARMISTICE CAPITAL, LLC
$324.5K141,397 sh
GEODE CAPITAL MANAGEMENT, LLC
$47.8K20,840 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.3K5,810 sh
UBS Group AG
$13.2K5,735 sh
VANGUARD FIDUCIARY TRUST CO
$9.1K3,958 sh
Tower Research Capital LLC (TRC)
$7.5K3,280 sh
OSAIC HOLDINGS, INC.
$460.00200 sh
BARCLAYS PLC
$326.00142 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$324.5K	141,397
GEODE CAPITAL MANAGEMENT, LLC	$47.8K	20,840
VANGUARD CAPITAL MANAGEMENT LLC	$13.3K	5,810
UBS Group AG	$13.2K	5,735
VANGUARD FIDUCIARY TRUST CO	$9.1K	3,958
Tower Research Capital LLC (TRC)	$7.5K	3,280
OSAIC HOLDINGS, INC.	$460.00	200
BARCLAYS PLC	$326.00	142

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INBS on your watchlist

Track score changes the day INTELLIGENT BIO SOLUTIONS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INBS a good stock to buy?

13F Pro's AI-powered analysis of INTELLIGENT BIO SOLUTIONS INC. (INBS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INBS are available on the INBS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INBS is classified as a small company.

Which hedge funds own INBS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INBS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INTELLIGENT BIO SOLUTIONS INC.'s investment landscape.